Ceribell Inc. (NASDAQ: CBLL) Chief Financial Officer Scott Blumberg sold 1,521 common shares on August 21, 2026, for a total of $36,534 at $24.02 per share. The disposal was executed to cover tax withholding obligations tied to the vesting of restricted stock units.
Blumberg retains 146,600 shares of Ceribell common stock following the transaction. The stock has traded near its 52-week high of $25.33 in recent sessions, reflecting a 109% gain over the past year.
Ceribell reported second-quarter fiscal 2026 revenue of $28.1 million, a 33% year-over-year increase that accelerated from 29% growth in the prior quarter. The company reported a net loss of $0.51 per share, wider than the $0.36 per share loss forecast by analysts.
Ceribell operates in seizure detection and is developing products for delirium monitoring and pediatric care. Analysts at Canaccord raised the price target to $26 from $25 while maintaining a buy rating, citing strong quarterly results. BTIG increased its target to $30 from $28, emphasizing the company’s leadership in rapid point-of-care EEG technology.
